Exploring the Indoor Plant-People Relationship Through Qualitative Responses.

Humans have a long-standing relationship with the natural world, particularly in how they engage with plants-referred to as people-plant relationships. While plants naturally live outdoors, people have been including them inside built environments for centuries. Although the benefits of indoor plants are well documented in research, there is limited exploration of individuals' subjective relationships with their indoor plants.

Developing and validating an intervention-specific knowledge assessment for person-centered communication in nursing home continuing education.

Purpose: The assessment of knowledge gain from educational interventions is a common practice in dementia care research. This study aimed to refine and validate the Changing Talk Scale (CHATS), a tool for assessing knowledge of effective and person-centered communication in nursing home staff. CHATS was integrated into the Changing Talk: Online (CHATO) education program to measure the knowledge gains resulting from it.

Sex-specific DNA methylation differences in Amyotrophic lateral sclerosis.

Sex is an important covariate in all genetic and epigenetic research due to its role in the incidence, progression and outcome of many phenotypic characteristics and human diseases. Amyotrophic lateral sclerosis (ALS) is a motor neuron disease with a sex bias towards higher incidence in males. Here, we report for the first time a blood-based epigenome-wide association study meta-analysis in 9274 individuals after stringent quality control (5529 males and 3975 females).

Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.

Background: Coadministration of a respiratory syncytial virus (RSV) vaccine with seasonal influenza or SARS-CoV-2 vaccines could reduce health-care visits and increase vaccination uptake in older adults who are at high risk for severe respiratory disease. The RSV mRNA-1345 vaccine demonstrated efficacy against RSV disease with acceptable safety in the ConquerRSV trial in adults aged 60 years and older. We aimed to evaluate the safety and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine or SARS-CoV-2 mRNA vaccine.